| Imaging Lung Disease in Systemic Sclerosis |
 |
 |
 |
| Thursday, 17 June 2010 08:19 |
|
Diane Strollo & Jonathan Goldin
Published online: 16 March 2010
Copyright, The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Interstitial lung disease and pulmonary hypertension (PH) are the most common cardiopulmonary findings in patients with systemic sclerosis (SSc). About two thirds of patients suffering from SSc develop scleroderma interstitial lung disease. PH is present in about 20% of
SSc patients and is typically associated with severe lung disease, although it may be an isolated manifestation of SSc. High-resolution CT scanning is a key method for evaluating chest involvement. There are four roles of imaging in scleroderma interstitial lung disease: 1) detection of lung involvement, 2) identification of patients likely to respond to treatment, 3) assessment of treatment efficacy, and 4) exclusion of other significant diseases to include PH and cardiac and esophageal abnormalities. Diane Strollo & Jonathan Goldin Published online: 16 March 2010 Copyright, The Author(s) 2010. This article is published with open access at Springerlink.com Abstract Interstitial lung disease and pulmonary hypertension (PH) are the most common cardiopulmonary findings in patients with systemic sclerosis (SSc). About two thirds of patients suffering from SSc develop scleroderma interstitial lung disease. PH is present in about 20% of SSc patients and is typically associated with severe lung disease, although it may be an isolated manifestation of SSc. High-resolution CT scanning is a key method for evaluating chest involvement.
There are four roles of imaging in scleroderma interstitial lung disease: 1) detection of lung involvement, 2) identification of patients likely to respond to treatment, 3) assessment of treatment efficacy, and 4) exclusion of other significant diseases to include PH and cardiac and esophageal abnormalities. Login to download your own copy of the full and original article from the link provided below. |
More articles :
» Understanding The Female Bias For Autoimmune Diseases
The reasons why women are so much more commonly affected by autoimmune disease have largely remained a complex mystery. Now, however, researchers from the have identified a previously unknown type of B cell in aged female mice and in young...
» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials
Ann J. Impens, Kristine Phillips, and Elena SchiopuReceived 2 June 2011; Accepted 2 August 2011Phosphodiesterases (PDEs) are isoenzymes that control the level of intracellular cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate...
» Optical Coherence Tomography: The first Quantitative Imaging Biomarker for Scleroderma
Using the , manufactured in the UK by Michelson Diagnostics Ltd, scientists at the Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds have developed the first quantitative imaging biomarker for skin involvement in . Scleroderma...
» What Is Autoimmune Hepatitis?
Autoimmune hepatitis is an of the caused by an autoimmune disorder. An autoimmune disorder is one in which a person's immune system attacks his or her own body for unknown reasons. The degree of liver inflammation can range from mild to deadly.The...
» An Approach to the Treatment of Scleroderma
Systemic sclerosis is unique among the rheumatic diseases because it presents the challenge of managing a chronic multisystem autoimmune disease with a widespread obliterative vasculopathy of small arteries that is associated with varying degrees of...
» Development of an Activity Index for Localized Scleroderma (Morphea)
E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...